International Journal of Infectious Diseases (Jan 2022)

Identifying Epstein–Barr virus peptide sequences associated with differential IgG antibody response

  • Anna E. Coghill,
  • Jianwen Fang,
  • Zhiwei Liu,
  • Chien-Jen Chen,
  • Ruth F. Jarrett,
  • Henrik Hjalgrim,
  • Carla Proietti,
  • Kelly J. Yu,
  • Wan-Lun Hsu,
  • Pei-Jen Lou,
  • Chen-Ping Wang,
  • Yingdong Zhao,
  • Denise L. Doolan,
  • Allan Hildesheim

Journal volume & issue
Vol. 114
pp. 65 – 71

Abstract

Read online

ABSTRACT: Background: Epstein–Barr virus (EBV) infection contributes to cancers in a fraction of seropositive individuals, but much remains to be learned about variation in EBV-directed humoral immunity in cancer-free adults. Methods: A protein microarray was used to probe serum from 175 Taiwanese and 141 Northern European adults for immunoglobulin G (IgG) antibody responses to 115 different peptide sequences, representing protein segments or protein variants, from 45 EBV proteins. It was posited that this antibody-based approach could identify EBV peptide sequences representing immunodominant regions relevant for B-cell immunity. Results: Analyses of 45 EBV proteins with multiple protein segments or variants printed on the array identified eight EBV peptide sequences that appear to play a role in immunogenicity. This included: (1) three proteins with segments/regions associated with IgG reactivity (BALF5, LMP1, LMP2A); and (2) five proteins with sequence variants/amino acid changes associated with IgG reactivity (BDLF4, EBNA3A, EBNA3B, EBNA-LP, LF1). Conclusion: This examination of IgG antibody responses against 115 EBV peptide sequences in 316 cancer-free adults represents an important step toward identifying specific EBV protein sequences that play a role in generating B-cell immunity in humans.

Keywords